These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 15615349)

  • 1. [Intestinal cholesterol absorption: a pharmacological target for lowering of plasma cholesterol].
    Catapano AL; Catapano L; Fellin R
    Ital Heart J Suppl; 2004 Oct; 5(10):779-84. PubMed ID: 15615349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
    Daskalopoulou SS; Mikhailidis DP
    Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hyperlipidemia: therapeutic principles in clinical practice].
    Müller-Wieland D; Krone W
    Med Klin (Munich); 2003 Dec; 98(12):739-43. PubMed ID: 14685674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hypercholesterolemia, cardiovascular risk, and hypocholesteremic treatment in the elderly].
    Cicconetti P; Ciotti V; Tafaro L; Riolo N; Marigliano V
    Recenti Prog Med; 2002 Apr; 93(4):264-72. PubMed ID: 11989134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Cheng AY; Leiter LA
    Curr Opin Cardiol; 2006 Jul; 21(4):400-4. PubMed ID: 16755211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of high-risk older persons with lipid-lowering drug therapy.
    Aronow WS
    Am J Ther; 2008; 15(2):102-7. PubMed ID: 18356628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on lipid-lowering therapy and LDL-cholesterol targets.
    Wiviott SD; Cannon CP
    Nat Clin Pract Cardiovasc Med; 2006 Aug; 3(8):424-36. PubMed ID: 16874355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical appraisal of revised cholesterol guidelines for the very high-risk patient.
    Rosenson R; Lloyd-Jones D;
    Expert Rev Cardiovasc Ther; 2005 Jan; 3(1):173-8. PubMed ID: 15739256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lowering LDL cholesterol in adults: a prospective, community-based practice initiative.
    Coodley GO; Jorgensen M; Kirschenbaum J; Sparks C; Zeigler L; Albertson BD
    Am J Med; 2008 Jul; 121(7):604-10. PubMed ID: 18538295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
    McKenney JM
    Am J Cardiol; 2005 Aug; 96(4A):60E-66E. PubMed ID: 16098846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ezetimib and simvastatin. Cooperation at receptors of cholesterol metabolism].
    MMW Fortschr Med; 2005 Jul; 147(27-28):50. PubMed ID: 16041947
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
    Gotto AM; Farmer JA
    Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):664-72. PubMed ID: 17122799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lowering cholesterol: how low is low enough?].
    Czuriga I; Edes I
    Orv Hetil; 2006 Jul; 147(29):1349-56. PubMed ID: 16941825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
    Robinson JG
    Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid lowering goals: back to nature?
    Hochholzer W; Giugliano RP
    Ther Adv Cardiovasc Dis; 2010 Jun; 4(3):185-91. PubMed ID: 20400493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Stanols--a new perspective in treatment of hypercholesterolemia?].
    Jankowski P; Bilo G; Bryniarski L; Bryniarska-Mirek E; Pajak A
    Przegl Lek; 2000; 57(11):655-8. PubMed ID: 11293214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Statins plus inhibition of cholesterol absorption. Dual mechanism of action in lipid therapy].
    MMW Fortschr Med; 2002 Sep; 144(35-36):51. PubMed ID: 12380358
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.